NCT01010945 is a Phase 1 clinical trial of erlotinib in Advanced Pancreatic Cancer, sponsored by OSI Pharmaceuticals.

Who is sponsoring NCT01010945?

NCT01010945 is sponsored by OSI Pharmaceuticals.

What drugs are being tested in NCT01010945?

Interventions in NCT01010945: erlotinib, gemcitabine, nab-paclitaxel.

What condition does NCT01010945 study?

NCT01010945 studies Advanced Pancreatic Cancer.

Is NCT01010945 still recruiting?

NCT01010945 is currently completed. Last updated 21 November 2024.

Last reviewed 2024-11-21 · How we verify

NCT01010945

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer

Completed Phase 1 Last updated 21 November 2024

What this trial tests

Phase 1 trial testing erlotinib in Advanced Pancreatic Cancer in 19 participants. Completed in 25 January 2012.

Timeline

3 February 2010

Primary endpoint
25 January 2012

25 January 2012

Quick facts

Lead sponsor	OSI Pharmaceuticals
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	19
Start date	3 February 2010
Primary completion	25 January 2012
Estimated completion	25 January 2012
Sites	5 locations across United States

Drugs / interventions tested

erlotinib (erlotinib) — full drug profile →
gemcitabine (gemcitabine) — full drug profile →
nab-paclitaxel (nab-paclitaxel) — full drug profile →

Conditions studied

Advanced Pancreatic Cancer — all drugs for Advanced Pancreatic Cancer →

Sponsor

OSI Pharmaceuticals — full company profile →

Who can join

18 and older, any sex, with Advanced Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase 1b study to evaluate the combination of gemcitabine and Tarceva (erlotinib) and nab-paclitaxel in patients with advanced pancreatic cancer.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Therapeutically reprogrammed nutrient signalling enhances nanoparticulate albumin bound drug uptake and efficacy in KRAS-mutant cancer.
Li R, Ng TSC, Wang SJ, Prytyskach M, et al · · 2021 · cited 94× · PMID 33958764 · DOI 10.1038/s41565-021-00897-1
Metastatic pancreatic cancer: Is there a light at the end of the tunnel?
Vaccaro V, Sperduti I, Vari S, Bria E, et al · · 2015 · cited 49× · PMID 25944992 · DOI 10.3748/wjg.v21.i16.4788

Verify or expand the search:

Other trials of erlotinib

Trials testing the same drug.

NCT05834348 — A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in N · completed
NCT05904457 — A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer · Phase 2 · unknown
NCT02991651 — Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC · Phase 1 · terminated
NCT02468661 — A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Me · Phase 1 · terminated
NCT02057380 — A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial · Phase 2 · completed

Other recruiting trials for Advanced Pancreatic Cancer

Currently open trials in the same condition.

NCT07416240 — Exploratory Clinical Study of Claudin18.2-Targeted Activated DC and CAR-T Therapy in Advanced Pancreatic Cancer. · EARLY_PHASE1 · recruiting
NCT07006077 — Recombinant Human IL-21-expressing Oncolytic Vaccinia Virus Injection (hV01) in Advanced Pancreatic Cancer · Phase 2 · recruiting
NCT06111274 — A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer · Phase 2 · recruiting
NCT06078787 — Olaparib in PALB2 Advanced Pancreatic Cancer · Phase 2 · recruiting
NCT05916261 — Personalized Tumor Vaccines and Pabolizumab in Patients With Advanced Pancreatic Cancer · EARLY_PHASE1 · recruiting

Other OSI Pharmaceuticals trials

Trials by the same sponsor.

NCT01247922 — Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205 · Phase 2 · terminated
NCT01032070 — Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma · Phase 2 · terminated
NCT00139620 — A Pharmacokinetic Study of Erlotinib in Cancer Patients With Advanced Solid Tumors, With Adequate and Moderately Impaire · Phase 1 · completed
NCT00072631 — Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer · Phase 2 · completed
NCT00040183 — OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer. · Phase 3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01010945 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by OSI Pharmaceuticals
Last refreshed: 21 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01010945.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing